Sales and Marketing

Showing 15 posts of 11528 posts found.

Pfizer notches two EU approvals, including Herceptin biosimilar

August 1, 2018 Research and Development, Sales and Marketing Cancer, EMA, EU, Genetech, Herceptin, Pfizer, Trazimera, Xeljanz, biosimilar, breast cancer, pharma

Pfizer is patting itself on the back after securing two new approvals in Europe within 24 hours: Xeljanz (tofacitinib citrate) …

Novartis migraine prevention drug scores EU approval

July 31, 2018 Manufacturing and Production, Sales and Marketing Aimovig, Europe, Novartis, migraine, pharma

Novartis is celebrating the news that its calcitonin gene-related peptide receptor (CGRP-R) pathway therapy Aimovig (erenumab) has been approved by …

Progenics’ Azedra becomes first FDA-approved treatment for adrenal tumours

July 31, 2018 Manufacturing and Production, Sales and Marketing Cancer, FDA, Progenics, adrenal cancer, pharma

The FDA has approved its first-ever drug for rare, unresectable tumours of the adrenal gland with its decision to authorise …

Wockhardt launches $40m manufacturing plant in Dubai

July 30, 2018 Manufacturing and Production, Sales and Marketing Antibiotics, Dubai, India, Wockhardt, antibiotic resistance, pharma

Indian pharmaceutical firm Wockhardt has launched its first manufacturing facility in Dubai’s Jebel Ali Free Zone (Jafza). Costing $40 million, …

EU Commission grants market authorisation for Sandoz’ Humira biosimilar

July 30, 2018 Sales and Marketing FDA, Sandoz, approval, biosimilar, european commision

The European Commission has granted marketing authorisation to Sandoz’ biosimilar Hyrimoz for use in all indications, including rheumatoid arthritis, plaque …

Gilead’s CEO and Chairman to both step down before year’s end

July 30, 2018 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Gilead, pharma

Gilead has announced that its President and Chief Executive Officer Dr John Milligan (pictured) will be stepping down by the …

Living with Behçet’s disease

July 30, 2018 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Behçet's disease, patient experience, pharma

Suzanne Morris speaks to Pharmafocus to discuss her life with Behçet’s disease, a rare condition characterised by the inflammation of …

CHMP recommend white blood cell growth stimulator biosimilar to EMA

July 30, 2018 Sales and Marketing Amgen, CHMP, EMA, Neulasta, biosimilar, chemotherapy, pegfilgrastim

The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of two separate …

Tonix plunges 68% after PTSD drug failure

July 30, 2018 Research and Development, Sales and Marketing PTSD, Tonmya, pharma, tonix

Tonix Pharmaceuticals has announced that it has terminated its Phase 3 study of Tonmya (cyclobenzaprine HCl sublingual tablets) in military-related …

Army to ferry medicines in case of no-deal Brexit

July 30, 2018 Sales and Marketing UK, army, brexit, medicines, pharma, politics, supply chains

Ministers have established plans to use the army to deliver medicines, food and fuel in the event of a no-deal …

Amgen announces resignation of two top executives

July 27, 2018 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, Anthony C Cooper, R&D, biotech, retire, sean harper

Amgen’s head of R&D, Dr Sean Harper, has announced that he is retiring from his current position as Executive Vice …

Gilead’s CEO and Chairman to both step down before year’s end

July 26, 2018 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Gilead, pharma

Gilead has announced that its President and Chief Executive Officer Dr John Milligan (pictured) will be stepping down by the …

AstraZeneca announces price freezes while earnings drop by 28%

July 26, 2018 Business Services, Sales and Marketing AstraZeneca, Trump, price freezes, price hikes

The Anglo-Swedish drug maker AstraZeneca has joined Pfizer and others in halting price hikes until the end of 2018. AstraZeneca …
The Gateway to Local Adoption Series

Latest content